检查了次优自评健康 (SRH) 的患病率及其与血液或骨髓移植 (BMT) 后随后的全因和特定原因死亡率的关系。研究参与者来自多中心血液或骨髓移植幸存者研究，并且包括 1974 年至 2014 年间接受移植且 BMT 后存活≥2 年的患者。参与者（年龄≥18岁）在BMT后中位9年完成调查，并在调查完成后中位随访5.6年。幸存者提供了有关社会人口因素、慢性健康状况、健康行为和 SRH 的信息（单项测量被评为优秀、非常好、良好、一般或较差；优秀、非常好和良好的 SRH 被归类为良好的 SRH，一般和较差被归类为次优 SRH）。 National Death Index Plus 和 Accurint 数据库和医疗记录提供了截至 2021 年 12 月的生命状况。在 3739 名参与者中，784 人在调查完成后死亡（21%）。总体而言，879 名 BMT 幸存者 (23.5%) 报告 SRH 不理想。疼痛、社会经济地位低、心理困扰、缺乏锻炼、严重/危及生命的慢性健康状况、BMT 后复发、肥胖、吸烟和男性与次优的 SRH 相关。报告 SRH 不理想的 BMT 幸存者全因死亡风险增加 1.9 倍（95% 置信区间 [CI]，1.6-2.3），复发相关死亡风险增加 1.8 倍（95% CI，1.4-2.5） ），与那些报告良好 SRH 的人相比，非复发相关死亡率的风险增加了 1.9 倍（95% CI，1.4-2.4）。这一单项指标可以帮助识别弱势亚群，他们可以从减轻风险的干预措施中受益。随后死亡的风险。© 2024 美国癌症协会。

The prevalence of suboptimal self-rated health (SRH) and its association with subsequent all-cause and cause-specific mortality after blood or marrow transplantation (BMT) were examined.Study participants were drawn from the multicenter Blood or Marrow Transplant Survivor Study, and included patients who were transplanted between 1974 and 2014 and had survived ≥2 years after BMT. Participants (aged ≥18 years) completed a survey at a median of 9 years from BMT, and were followed for a median of 5.6 years after survey completion. Survivors provided information on sociodemographic factors, chronic health conditions, health behaviors, and SRH (a single-item measure rated as excellent, very good, good, fair, or poor; excellent, very good, and good SRH were classified as good SRH, and fair and poor were classified as suboptimal SRH). The National Death Index Plus and Accurint databases and medical records provided vital status through December 2021.Of 3739 participants, 784 died after survey completion (21%). Overall, 879 BMT survivors (23.5%) reported suboptimal SRH. Pain, low socioeconomic status, psychological distress, lack of exercise, severe/life-threatening chronic health conditions, post-BMT relapse, obesity, smoking, and male sex were associated with suboptimal SRH. BMT survivors who reported suboptimal SRH had a 1.9-fold increased risk of all-cause mortality (95% confidence interval [CI], 1.6-2.3), 1.8-fold increased risk of recurrence-related mortality (95% CI, 1.4-2.5), and 1.9-fold increased risk of non-recurrence-related mortality (95% CI, 1.4-2.4) compared to those who reported good SRH.This single-item measure could help identify vulnerable subpopulations who could benefit from interventions to mitigate the risk for subsequent mortality.© 2024 American Cancer Society.